AZN

AstraZeneca PLC (AZN) Investor Outlook: Analyzing Growth Potential with a 9.40% Upside

AstraZeneca PLC (AZN), a titan in the healthcare sector, is renowned for its robust portfolio of prescription medicines that cater to a broad spectrum of medical needs. From oncology to..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 17.78% Potential Upside

AstraZeneca PLC (AZN), a leading player in the healthcare sector, continues to capture investor interest with its robust pipeline and strategic collaborations. Headquartered in Cambridge, UK, AstraZeneca specializes in the..

AstraZeneca PLC (AZN) Stock Analysis: A Robust 17.12% Potential Upside Captures Investor Attention

AstraZeneca PLC (AZN) stands as a formidable player in the healthcare sector, particularly within the drug manufacturing industry. Based in Cambridge, United Kingdom, the company boasts a substantial market capitalization..

AstraZeneca PLC (AZN): Investor Outlook Highlights Promising 18.20% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a global powerhouse in the biopharmaceutical sector, continues to capture investor attention with its robust market presence and a promising potential upside of 18.20%. As a..

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca PLC (AZN) Investor Outlook: Examining a 22.38% Potential Upside

AstraZeneca PLC (AZN), a titan in the healthcare sector and a leader among general drug manufacturers, presents a compelling investment opportunity. With a market capitalization of $214.36 billion, this UK-based..

AstraZeneca PLC (AZN) Stock Analysis: Exploring an 18.35% Potential Upside Amid Robust Growth Prospects

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its impressive market capitalization of $223.9 billion and promising growth trajectory. As a leading biopharmaceutical..

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all..

AstraZeneca PLC (AZN) Stock Analysis: Examining a Potential 21% Upside for Savvy Investors

AstraZeneca PLC (AZN), a stalwart in the global healthcare sector, remains an attractive proposition for investors, with a substantial market cap of $215.91 billion. Headquartered in Cambridge, United Kingdom, AstraZeneca..

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

Astrazeneca PLC (AZN)

⚠️ No article content returned.

..

AstraZeneca Secures U.S. FDA Accelerated Approval for Datroway in EGFR-Mutated NSCLC

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

AstraZeneca PLC (AZN) Stock Analysis: Unpacking a 20% Potential Upside for Investors

AstraZeneca PLC (NASDAQ: AZN), a biopharmaceutical titan headquartered in Cambridge, the United Kingdom, is currently drawing significant attention from investors who are keenly observing its promising potential upside of 20.35%...

AstraZeneca PLC (AZN): Investor Outlook Highlights 13.12% Potential Upside and Strong Buy Ratings

AstraZeneca PLC (AZN), a titan in the global healthcare sector, continues to capture investor attention with its robust pipeline and strategic collaborations aimed at revolutionizing drug development. Listed on major..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 15.51% Potential Upside with Strong Buy Ratings

AstraZeneca PLC (NASDAQ: AZN), a titan in the healthcare sector, continues to capture investor attention with its robust portfolio of prescription medicines and strategic innovations. With a market capitalization of..

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

AstraZeneca PLC (AZN) Stock Analysis: Navigating a 15.59% Potential Upside Amid Robust Dividend Yield

AstraZeneca PLC (AZN), a leading biopharmaceutical giant based in Cambridge, United Kingdom, stands out in the healthcare sector with an impressive market capitalization of $225.8 billion. Known for its innovation..

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 20% Potential Upside for Investors

AstraZeneca PLC (NASDAQ: AZN), a heavyweight in the healthcare sector and a celebrated name in the global pharmaceutical landscape, offers a compelling opportunity for investors. With a robust market capitalization..

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
Search

Funds

AZN

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

AstraZeneca Secures U.S. FDA Accelerated Approval for Datroway in EGFR-Mutated NSCLC

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
Search

Funds

AZN

FTSE 100

Funds